ArticleAdvanced genetics (Hoboken, N.J.)2026
Compact Cas12 Systems for Multiplex Engineering of Plant Abiotic-Stress Networks.
Article in Advanced genetics (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compact CRISPR-Cas12 platforms, particularly miniature and hypercompact effectors such as Cas12f, Cas12j/CasPhi, and Cas12lambda, are emerging as delivery-efficient tools for plant genome engineering because their reduced coding size facilitates viral-replicon and other size-constrained delivery routes while supporting dense guide multiplexing. Here, we argue that their highest value for crop improvement lies not simply in additional nuclease choices, but in programmable, systems-level tuning of abiotic-stress defense layers, including ion homeostasis, redox buffering, osmotic adjustment, abscisic acid (ABA)-centered hormone signaling, and transcriptional control. We distinguish evidence already demonstrated in stable plants, transient plant assays, or protoplasts from approaches extrapolated from Cas9/Cas12a or non-plant systems, and emphasize that many compact Cas12 applications remain platform-building rather than field-ready technologies. Current plant evidence supports Cas12a as a mature multiplex-editing and transcriptional-repression platform, Cas12f as a rapidly improving mini-editor with stable and viral-delivery demonstrations, and Cas12j/CasPhi as a hypercompact system with recent crop-editing and base-editing potential. By contrast, Cas12g, Cas12h, Cas12lambda, and TnpB-like nucleases are best viewed as promising future modules until plant-active implementations are broadly validated. We offer a forward-looking roadmap in which compact Cas12 systems complement Cas9 and Cas12a by enabling rapid target triage, promoter and untranslated-region engineering, transient CRISPR activation/interference, and stepwise assembly of durable sentinel edits. Translation will depend on improving efficiency and fidelity across genotypes, reducing mosaicism, documenting off-target and structural variation in multiplex stacks, and aligning delivery strategies with regulatory expectations for transgene-free crops.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.